These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 15641876)

  • 21. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators.
    Lecrubier Y; Judge R
    Acta Psychiatr Scand; 1997 Feb; 95(2):153-60. PubMed ID: 9065681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.
    Wagner KD; Berard R; Stein MB; Wetherhold E; Carpenter DJ; Perera P; Gee M; Davy K; Machin A
    Arch Gen Psychiatry; 2004 Nov; 61(11):1153-62. PubMed ID: 15520363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?
    Geller DA; Biederman J; Stewart SE; Mullin B; Farrell C; Wagner KD; Emslie G; Carpenter D
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S19-29. PubMed ID: 12880497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.
    Figgitt DP; McClellan KJ
    Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse.
    Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M
    J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder.
    Bakker A; van Dyck R; Spinhoven P; van Balkom AJ
    J Clin Psychiatry; 1999 Dec; 60(12):831-8. PubMed ID: 10665629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxetine and its uses in psychiatry.
    Bell C; Nutt D
    Hosp Med; 1999 May; 60(5):353-6. PubMed ID: 10396411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies.
    Stein DJ; Davidson J; Seedat S; Beebe K
    Expert Opin Pharmacother; 2003 Oct; 4(10):1829-38. PubMed ID: 14521492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
    Book SW; Thomas SE; Randall PK; Randall CL
    J Anxiety Disord; 2008; 22(2):310-8. PubMed ID: 17448631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experience with paroxetine in social anxiety disorder.
    Baldwin DS
    Int Clin Psychopharmacol; 2000 Jul; 15 Suppl 1():S19-24. PubMed ID: 10994679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of paroxetine in generalised social anxiety disorder.
    Van Ameringen M; Mancini C; Patterson B; Bennett M
    Expert Opin Pharmacother; 2005 May; 6(5):819-30. PubMed ID: 15934907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
    Lee JH; Dunner DL
    Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.
    Zohar J; Westenberg HG
    Acta Psychiatr Scand Suppl; 2000; 403():39-49. PubMed ID: 11019934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. To what extent does the anxiety scale of the Four-Dimensional Symptom Questionnaire (4DSQ) detect specific types of anxiety disorder in primary care? A psychometric study.
    Terluin B; Oosterbaan DB; Brouwers EP; van Straten A; van de Ven PM; Langerak W; van Marwijk HW
    BMC Psychiatry; 2014 Apr; 14():121. PubMed ID: 24761829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.
    Sheehan DV; Burnham DB; Iyengar MK; Perera P;
    J Clin Psychiatry; 2005 Jan; 66(1):34-40. PubMed ID: 15669886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders.
    Gunasekara NS; Noble S; Benfield P
    Drugs; 1998 Jan; 55(1):85-120. PubMed ID: 9463792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacological management of childhood anxiety disorders: a review.
    Reinblatt SP; Riddle MA
    Psychopharmacology (Berl); 2007 Mar; 191(1):67-86. PubMed ID: 17205317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic subgroups for remission and response in the Coordinated Anxiety Learning and Management (CALM) trial.
    Kelly JM; Jakubovski E; Bloch MH
    J Clin Psychiatry; 2015 Mar; 76(3):267-78. PubMed ID: 25562579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The differential diagnosis of anxiety. Psychiatric and medical disorders.
    Cameron OG
    Psychiatr Clin North Am; 1985 Mar; 8(1):3-23. PubMed ID: 3887337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.
    Bourin M
    Hum Psychopharmacol; 2003 Apr; 18(3):185-90. PubMed ID: 12672169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.